Ascentage Pharma Group International (NASDAQ:AAPG) vs. X4 Pharmaceuticals (NASDAQ:XFOR) Critical Contrast

X4 Pharmaceuticals (NASDAQ:XFOR) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

X4 Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Ascentage Pharma Group International has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for X4 Pharmaceuticals and Ascentage Pharma Group International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	1	4	0	2.50
Ascentage Pharma Group International	0	0	8	2	3.20

X4 Pharmaceuticals currently has a consensus price target of $9.38, suggesting a potential upside of 129.22%. Ascentage Pharma Group International has a consensus price target of $46.43, suggesting a potential upside of 158.51%. Given Ascentage Pharma Group International’s stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than X4 Pharmaceuticals.

Earnings and Valuation

This table compares X4 Pharmaceuticals and Ascentage Pharma Group International”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11 million	10.99	-$79.20 million	($4.54)	-0.90
Ascentage Pharma Group International	$82.10 million	20.43	-$177.71 million	N/A	N/A

X4 Pharmaceuticals has higher earnings, but lower revenue than Ascentage Pharma Group International.

Profitability

This table compares X4 Pharmaceuticals and Ascentage Pharma Group International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Ascentage Pharma Group International	N/A	N/A	N/A

Summary

Ascentage Pharma Group International beats X4 Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.